AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie elahere (mirvetuximab soravtansine) — Worldwide net revenues ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues
Latest, FY2025
690
Period ended Dec 31, 2025
Change on a year earlier
+44.1%
479 in FY2024
History
4 years
Since FY2022
Sources
2
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Elahere (mirvetuximab soravtansine) — Worldwide net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 690 | +44.1% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 479 | – | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 0 | – | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 0 | – | Form 10-K (filed 2025-02-14) ↗ |
Breakdown
What makes up elahere (mirvetuximab soravtansine) — worldwide net revenues ($m)
- Elahere (mirvetuximab soravtansine) — U.S. net revenues ($M)607 · FY2025
- Elahere (mirvetuximab soravtansine) — International net revenues ($M)83 · FY2025
- Elahere (mirvetuximab soravtansine) — Worldwide reported growth YoY (%)44.0% · FY2025
- Elahere (mirvetuximab soravtansine) — Worldwide operational (constant-currency) growth YoY (%)43.4% · FY2025
Cite this data
StockData. (2026). AbbVie Elahere (mirvetuximab soravtansine) — Worldwide net revenues ($M) ($M), annual FY2022–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/elahere_ww
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.